Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505661 · ClinicalTrials.gov registry record · Phase 2
Letrozole in Patients With Ovarian Tumors
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00505661: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00505661 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00505661, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Primary Objectives: * To determine the objective response rate of Letrozole when administered to patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary , fallopian tube or peritoneum. * To determine the time to tumor progression of patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary, fallopian tube or peritoneum. * To identify the biological markers to predict response to Letrozole and study the aspects of the hormones in these types of tumors.
Interventions
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2003-09 |
| Est. Completion | 2010-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505661
The ClinicalTrials.gov registry entry for NCT00505661 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letrozole is the first listed.
NCT00505661 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00505661 about?
NCT00505661 is a clinical study titled "Letrozole in Patients With Ovarian Tumors". Primary Objectives: * To determine the objective response rate of Letrozole when administered to patients with advanced or recurrent borderline tumors or low-grade epithelial cancers from the ovary , fallopian tube or peritoneum. * To determine the time to tumor progression of patients with advance...
What is the current status of trial NCT00505661?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2003-09. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00505661?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT00505661?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.